Drug Index


Synonyms :

G-CSF, Granulocyte Colony-Stimulating factor

Mechanism :

Filgrastim binds to the G-CSF receptor and stimulates the production of neutrophils in the bone marrow. As a G-CSF analog, it controls proliferation of committed progenitor cells and influences their maturation into mature neutrophils. Filgrastim also stimulates the release of neutrophils from bone marrow storage pools and reduces their maturation time. Filgrastim acts to increase the phagocytic activity of mature neutrophils. In patients receiving cytotoxic chemotherapy, Filgrastim can accelerate neutrophil recovery, leading to a reduction in duration of the neutropenic phase; endogenous G-CSF is a glycoprotein produced by monocytes, fibroblasts, and endothelial cells.

Indication :

  • Peripheral Blood Progenitor Cell Collection
  • Myelosuppressive Chemotherapy Treatment
  • Acute myeloid leukemia receiving induction or consolidation chemotherapy
  • Cancer patients receiving bone marrow transplant
  • Severe chronic neutropenia
  • In general, filgrastim increases neutrophil counts in order to decrease the risk of infection or duration of neutropenia in the aforementioned patient populations.

Contraindications :

Patients with known hypersensitivity to E. coli derived products or to any constituent of the product.

Dosing :

Pediatric Dose for Neutropenia Associated with Chemotherapy:
Initial dose: 5 mcg/kg/day as a single daily SC bolus injection, or short intravenous infusion (15 to 30 minutes) or by continuous subcutaneous or intravenous infusion.
Maintenance dose: 4 to 8 mcg/kg/day.
Duration of therapy: Up to 2 weeks, until the absolute neutrophil count reaches 10,000/mm³.
Congenital Neutropenia:
Initial dose: 6 mcg/kg subcutaneously twice a day.
Median dose: 6.0 mcg/kg/day.
Idiopathic or Cyclic Neutropenia:
Initial dose: 5 mcg/kg subcutaneously once a day.
Median dose:
Cyclic neutropenia: 2.1 mcg/kg/day.
Idiopathic neutropenia: 1.2 mcg/kg/day.

Adverse Effect :

Mild-to-moderately severe medullary bone pain, nausea, vomiting, hair loss, bone pain, peritonitis, fatigue, fever, and diarrhea, headache, shortness of breath, weight loss, mouth sores, rash, heart attacks, abnormal heart rhythm. Uric acid, lactate dehydrogenase, and alkaline phosphatase levels may rise and spontaneously return to normal levels.

Interaction :

The safety, efficacy, and possible interactions of filgrastim used in combination with other cytokines have not been characterized in clinical trials. Drugs which may potentiate the release of neutrophils, such as lithium, should be used with caution.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function and titrate dose to response
10-20Dose as in normal renal function and titrate dose to response
<10Dose as in normal renal function and titrate dose to response

Dose in Patients undergoing Renal Replacement Therapies
CAPDNot dialysed. Dose as in GFR<10 mL/min
HDNot dialysed. Dose as in GFR<10 mL/min
HDF/High fluxNot dialysed. Dose as in GFR<10 mL/min
CAV/VVHDNot dialysed. Dose as in GFR=10– 20 mL/min

Hepatic Dose :

No dosage adjustment is recommended.
02/13/2024 17:29:16 Filgrastim
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0